STOCK TITAN

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Nuwellis announced the exercise of warrants generating $5.1 million in gross proceeds. This includes $3.8 million from the immediate exercise of warrants issued on April 30, 2024, at $2.10 per share, plus $1.3 million from warrant exercises over the last week. In exchange for the immediate exercise, the company will issue new Series I and Series II warrants to purchase up to 3,665,034 shares. The new warrants will have an exercise price of $1.94, with Series I having a 5-year term and Series II a 2-year term, both exercisable after 6 months. Ladenburg Thalmann & Co. Inc. served as the exclusive warrant inducement agent.

Nuwellis ha annunciato l'esercizio di warrants generando 5,1 milioni di dollari di proventi lordo. Questo include 3,8 milioni di dollari derivanti dall'esercizio immediato di warrants emessi il 30 aprile 2024, a 2,10 dollari per azione, oltre a 1,3 milioni di dollari da esercizi di warrants nell'ultima settimana. In cambio dell'esercizio immediato, l'azienda emetterà nuovi warrants di Serie I e Serie II per acquistare fino a 3.665.034 azioni. I nuovi warrants avranno un prezzo di esercizio di 1,94 dollari, con la Serie I avente un termine di 5 anni e la Serie II un termine di 2 anni, entrambi esercitabili dopo 6 mesi. Ladenburg Thalmann & Co. Inc. ha agito come agente esclusivo per l'induzione dei warrants.

Nuwellis anunció el ejercicio de warrants generando 5,1 millones de dólares en ingresos brutos. Esto incluye 3,8 millones de dólares del ejercicio inmediato de warrants emitidos el 30 de abril de 2024, a 2,10 dólares por acción, además de 1,3 millones de dólares de ejercicios de warrants en la última semana. A cambio del ejercicio inmediato, la empresa emitirá nuevos warrants de la Serie I y la Serie II para adquirir hasta 3.665.034 acciones. Los nuevos warrants tendrán un precio de ejercicio de 1,94 dólares, con la Serie I con un plazo de 5 años y la Serie II con un plazo de 2 años, ambos ejercitables después de 6 meses. Ladenburg Thalmann & Co. Inc. actuó como el agente exclusivo para la inducción de warrants.

Nuwellis는 510만 달러의 총 수익을 발생시키는 보증의 행사를 발표했습니다. 여기에는 2024년 4월 30일에 발행된 보증의 즉각적인 행사로 인한 380만 달러가 포함되며, 주당 2.10달러입니다. 또한, 지난 주 동안의 보증 행사로 130만 달러가 추가로 포함됩니다. 즉각적인 행사에 대한 대가로 회사는 최대 3,665,034주를 구매할 수 있는 새로운 시리즈 I 및 시리즈 II 보증을 발행할 것입니다. 새로운 보증의 행사가격은 1.94달러이며, 시리즈 I은 5년, 시리즈 II는 2년의 기간을 가지며, 둘 다 6개월 후에 행사할 수 있습니다. Ladenburg Thalmann & Co. Inc.는 독점적인 보증 유도 에이전트로 활동했습니다.

Nuwellis a annoncé l'exercice de warrants générant 5,1 millions de dollars de recettes brutes. Cela comprend 3,8 millions de dollars provenant de l'exercice immédiat de warrants émis le 30 avril 2024, à 2,10 dollars par action, ainsi que 1,3 millions de dollars provenant d'exercices de warrants au cours de la semaine dernière. En échange de l'exercice immédiat, la société émettra de nouveaux warrants de Série I et de Série II pour acquérir jusqu'à 3.665.034 actions. Les nouveaux warrants auront un prix d'exercice de 1,94 dollars, la Série I ayant un terme de 5 ans et la Série II un terme de 2 ans, les deux pouvant être exercés après 6 mois. Ladenburg Thalmann & Co. Inc. a agi en tant qu'agent exclusif pour l'induction des warrants.

Nuwellis gab die Ausübung von Warrants bekannt, die 5,1 Millionen Dollar Bruttoerlös generieren. Dies umfasst 3,8 Millionen Dollar aus der sofortigen Ausübung von Warrants, die am 30. April 2024 zu je 2,10 Dollar pro Aktie ausgegeben wurden, sowie 1,3 Millionen Dollar aus Warrants-Ausübungen in der letzten Woche. Im Gegenzug zur sofortigen Ausübung wird das Unternehmen neue Series I- und Series II-Warrants ausgeben, um bis zu 3.665.034 Aktien zu kaufen. Die neuen Warrants haben einen Ausübungspreis von 1,94 Dollar, wobei Series I eine Laufzeit von 5 Jahren und Series II eine Laufzeit von 2 Jahren hat, und beide nach 6 Monaten ausgeübt werden können. Ladenburg Thalmann & Co. Inc. fungierte als exklusiver Anreizagent für die Warrants.

Positive
  • Immediate cash injection of $5.1 million strengthening company's balance sheet
  • Successful warrant exercise indicating investor confidence
Negative
  • Potential future dilution from new warrant issuance of 3,665,034 shares
  • New warrants priced at $1.94, lower than previous $2.10 exercise price

Insights

The warrant exercise provides an immediate $5.1 million cash injection, significantly strengthening Nuwellis' balance sheet. The deal structure is complex but strategic - the company is incentivizing early warrant exercise at $2.10 per share by offering new warrants (Series I and II) with a lower strike price of $1.94. While this creates potential future dilution through 3.67 million new warrant shares, the immediate capital infusion enhances operational runway. The fixed-price nature of the new warrants provides clarity on potential dilution impact, though the 6-month exercise restriction helps manage near-term pressure. For a micro-cap company with a $5.4 million market cap, this financing represents a substantial capital raise that could fund key growth initiatives in the fluid overload treatment market.

MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.

Ladenburg Thalmann & Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants.

In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the “Series I Warrants”) and Series II common stock purchase warrants (the “Series II Warrants”) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features.

The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements.  The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, statements with respect to the completion of the offering and the satisfaction of customary closing conditions related to the offering. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offering, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS

INVESTORS:
Robert Scott
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com 

Vivian Cervantes
Gilmartin Group LLC
vivian.cervantes@gilmartinir.com 

Source: Nuwellis, Inc.


FAQ

How much did Nuwellis (NUWE) raise from warrant exercises in November 2024?

Nuwellis raised $5.1 million in gross proceeds, including $3.8 million from immediate warrant exercises at $2.10 per share and $1.3 million from recent warrant exercises.

What are the terms of Nuwellis's (NUWE) new Series I and II warrants issued in November 2024?

Both Series I and II warrants have a $1.94 exercise price and become exercisable after 6 months. Series I warrants have a 5-year term, while Series II warrants have a 2-year term.

How many new warrant shares did Nuwellis (NUWE) issue in November 2024?

Nuwellis issued new Series I and Series II warrants to purchase up to an aggregate of 3,665,034 shares of common stock.

Nuwellis, Inc.

NASDAQ:NUWE

NUWE Rankings

NUWE Latest News

NUWE Stock Data

5.25M
4.34M
1.6%
1.46%
17.27%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
EDEN PRAIRIE